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Abstract
Background & aims
Prognostic tests are critical in the management of patients with cirrhosis and ascites. Biolog-
ical tests or scores perform poorly in that situation. Mid-infrared fibre evanescent wave spec-
troscopy (MIR-FEWS) which allows for global serum metabolic profiling may provide more
relevant information by measuring a wider range of metabolic parameters in serum. Here
we present the accuracy of a MIR-FEWS based predictive model for the prognosis of 6
months survival in patients with ascites and cirrhosis.
Methods
Patients with ascites were prospectively included and followed up for 6 months. MIR-FEWS
spectra were measured in serum samples. The most informative spectral variables obtained
by MIR-FEWS were selected by FADA algorithm and then used to build the MIR model.
Accuracy of this model was assessed by ROC curves and 90%/10% Monte Carlo cross-vali-
dation. MIR model accuracy for 6 months survival was compared to that of the Child-Pugh
and MELD scores.
Results
119 patients were included. The mean age was 57.36±13.70, the MELD score was 16.32
±6.26, and the Child-Pugh score was 9.5±1.83. During follow-up, 23 patients died (20%).
The MIR model had an AUROC for 6 months mortality of 0.90 (CI95: 0.88–0.91), the MELD
0.77 (CI95: 0.66–0.89) and Child-Pugh 0.76 (CI95: 0.66–0.88). MELD and Child-Pugh AUR-
OCs were significantly lower than that of the MIR model (p = 0.02 and p = 0.02 respectively).
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Multivariate logistic regression analysis showed that MELD (p<0.05, OR:0.86;CI95:0.76–
0.97), Beta blockers (p = 0.036;OR:0.20;CI95:0.04–0.90), and the MIR model (p<0.001;
OR:0.50; CI95:0.37–0.66), were significantly associated with 6 months mortality.
Conclusions
In this pilot study MIR-FEWS more accurately assess the 6-month prognosis of patients
with ascites and cirrhosis than the MELD or Child-Pugh scores. These promising results, if
confirmed by a larger study, suggest that mid infrared spectroscopy could be helpful in the
management of these patients.
Introduction
Cirrhosis is associated with liver-related complications and mortality. Development of any of
these complications marks the transition from a compensated to an uncompensated state
which significantly decreases survival [1]. Prognosis of cirrhosis assessment is thus critical to
the management of patients, especially regarding prioritization for liver transplantation. How-
ever, it remains challenging due to the wide spectrum of the consequences of liver failure and
portal hypertension.
The Child-Pugh score was the first score developed to assess cirrhosis severity according to
biological and clinical criteria [2,3]. Although readily available and easy to determine, it uses
subjective variables that lower its reproducibility, and it does not account for renal function
which has a major impact on prognosis [4]. As a result, the MELD score was developed using a
robust statistical analysis [5,6]. It is based on continuous biological parameters (bilirubin, cre-
atinine, INR), and to date, is accepted as a more reproducible scoring method, although it does
not significantly outperform the accuracy of the Child-Pugh score [7]. However, unlike the
Child-Pugh score, the MELD score does not account for hepatic encephalopathy or ascites,
both having a critical prognostic impact [8,9].
The liver transplant waiting list recapitulates the challenges of prognosis assessment in
patients with cirrhosis. The ultimate goal for each patient is to optimize the trade-off between
organ availability and the risk of short-term mortality. The MELD score has been adopted to
increase priority for patients with a higher risk of death [10], however MELD exception points
have to be assigned to patients whose disease prognosis is not reflected by their MELD score
[11]. More specifically, the onset of ascites and refractory ascites are considered as major pejo-
rative steps not reflected by the MELD score [8]. Therefore there is still a need for a better
method to assess liver disease severity, which can encompass the wide spectrum of metabolic
alterations that may accompany cirrhosis, liver failure and portal hypertension.
Fibre Evanescent Wave Spectroscopy (FEWS) performed in the Mid Infrared (MIR) spec-
tral domain, allows for recording of a wide metabolic profile by simply placing a drop of
serum on a chalcogenide Glass fibre optic sensor and collecting an MIR absorption spectrum
[12,13]. MIR spectroscopy is based on the ability of organic molecular chemical bonds to
undergo vibrational transitions in the MIR region and generate absorption bands in specific
and thus assignable frequency ranges [14]. Evanescent wave is the part of the electromagnetic
field which propagates at the surface of a fibre when the IR beam is internally reflected at the
fibre/air interface. Evanescent waves can be absorbed by the chemical groups that are in close
contact with the fibre (Fig 1). Thus, putting a biological sample in contact with the fibre allows
for collecting at the fibre output, the biological sample’s absorption spectrum. The spectrum
MIR-FEWS for the prognosis of cirrhosis with ascites
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reflects the whole sample’s molecular organic composition, providing a metabolic fingerprint
[15] (Fig 2).
Many spectroscopy studies demonstrate the potential of MIR spectroscopy for medical
diagnosis, generally from tissue [17,18] and more recently from fluids like serum [19–21],
plasma [22,23], or tears [24]. In liver disease, pilot studies have unveiled the relevance of MIR
spectroscopy for the diagnosis of liver or bile duct cancer [25–27]. Feasibility studies per-
formed by our team have previously demonstrated that FEWS allows for fast and simple fluid
sampling, from which relevant metabolic fingerprints can be extracted [28][29]. Despite its
potential, MIR spectroscopy is not currently used in clinical practice, because most of these
studies were proof of concept studies [30].
The development of medical diagnosis based on vibrational spectroscopy is a two-phase proj-
ect: i) diagnosis or classification of biomarkers, and ii) identification of the collected biomarkers
[31]. The metabolic fingerprint acquired from MIR spectra allows for identification of the broad
biochemical alterations induced by the underlying disease. Spectral analysis and biomarker
identification are required to reduce the number of spectral variables (i.e. optical densities/wave-
numbers) from a few hundred to approximately a dozen, in order to minimize the influence of
noisy and/or redundant variables. This can be done through projection methods (PCA or PLS),
variable selection or a combination of both [32]. In biospectroscopy, most studies use projection
methods, however, these methods are detrimental to the spectral assignment of discriminative
variables and thus for interpretation of the model in its biochemical dimension. Furthermore,
projection methods may increase both noise and over-learning risk [32], consequently,other
methods were specifically designed for high-dimensional data, like the FADA algorithm [33].
The aim of this study is to evaluate the ability of MIR-FEWS to obtain a global metabolic
profile useful for the assessment of short-term prognosis of patients with ascites and cirrhosis.
For this purpose, the first part of this study presents the MIR spectroscopy accuracy for dis-
criminating 6 months survival, while biochemical assignment of the selected spectral markers
is proposed in the second part.
Patients and methods
Study population
Patients with cirrhosis and ascites, without hepatocellular carcinoma, admitted to the liver dis-
ease department between February 2012 and August 2013 for paracentesis, were consecutively
Fig 1. Mechanism of fibre evanescent wave spectroscopy (FEWS). A) Schematic propagation of the light
wave in the fibre. B) General set up for FEWS with the light direction from Mid Infra Red (MIR) light source
towards the detector. (With the agreement of Cui et al [16]).
https://doi.org/10.1371/journal.pone.0185997.g001
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included in this study. Hepatocellular carcinoma was ruled out at the first episode of ascites
then screened every six months according to EASL-ECORT guidelines [34].
The study was approved by the local ethic committee (Rennes University Hospital Ethical
Committee, n˚ 2011-A00580-41) and all patients gave their written informed consent.
History of liver disease including complications of cirrhosis, paracentesis volume and fre-
quency, and ongoing treatment (including beta blockers, diuretics and antibiotics prophylaxis)
were recorded at inclusion. A follow-up visit was performed six months after inclusion.
Patients transplanted before the follow-up visit were excluded from analysis.
Clinical data, including events related to liver failure or portal hypertension were recorded
at follow-up. Fasting blood samples were collected and the following biochemical assays were
performed at inclusion and the follow-up visit: serum creatinine, albumin, bilirubin, pro-
thrombin ratio, INR, sodium, AST, ALT, GGT, CRP and ALP. Child-Pugh and MELD scores
Fig 2. Representative spectra of a patient that was alive (blue) and a patient that was deceased (red) at
6 months. The frequency band assignments and absorption domains are displayed: blue, protein; orange,
lipids; green, nucleic acids; and dark brown, carbohydrates. ν and δ symbols describe the type of vibration: ν
depicts stretching and δ for bending, as for asymmetric and s for symmetric vibrational modes. A) Mid-infrared
absorbance spectrum. Analysis domain (3200–2800; 1800-950cm-1) is displayed as red lines. B) Second
derivatives spectra within the analysis domain.
https://doi.org/10.1371/journal.pone.0185997.g002
MIR-FEWS for the prognosis of cirrhosis with ascites
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were determined at inclusion and follow-up. Serum sample was frozen (-80˚C) until recording
for mid infrared spectra analyses.
All relevant data are available from the figshare repository at the following 10.6084/m9.
figshare.4753468.
Statistical analysis
Continuous variables were summarized as mean and standard deviation. All variables were
tested for normal distribution with the Shapiro-Wilk test. Comparisons were made using the
Student’s t-test for normally distributed data or with the Mann–Whitney U-test. Nominal data
were tested using the Fisher’s exact test.
Clinically significant variables and variables associated with 6-month survival in univariate
analysis with p<0.2, were included in logistic regression multivariate analysis with stepwise
forward selection according to Wald. For multivariate analysis p< 0.05 was considered
significant.
Diagnostic performance was determined using receiver operating characteristic (ROC)
curves and comparison of ROC curves according to Delong et al [35]. Cut-offs were deter-
mined using Youden index. Data were analyzed using SPSS version 22 (SPSS Inc., Chicago, IL,
USA). p< 0.05 was considered significant with a two-tailed test.
Fibre evanescent wave spectroscopy
Spectra acquisition. The MIR spectra were recorded using a Diafir SPID™ FTIR portable
spectrometer (Rennes, France). The FTIR spectra were acquired in absorption mode in the
4000–400 cm-1 frequency range. Nominal spectral resolution was set to 4 cm-1 and a zero filing
factor of 2 was employed, yielding a discrete spectral point spacing of 2 cm-1. The Blackman
Harris three-term apodization function was used for Fourier transform. The measurement
was performed by placing a single use infrared sensor (LS-23) in the spectrometer, recording
its background signal, and then depositing 7 μl of serum on the sensor. The single use design
eliminates possible cross-contamination between two samples. The spectrum was acquired 5
min after serum deposition to obtain an accurate signal/water ratio and remove excess water
that may conceal some infrared bands of interest. Water desorption was monitored over time
by observing the 3400 cm-1 water νO-H absorption band decrease.
Pre-treatments. MIR spectra were pre-processed and analyzed in the 3800–950 cm-1
wavenumber domain, where most of the biomolecules absorption are located. A straight line
was generated from 2800 to 1800 cm-1 to eliminate interference from ambient air CO2. Second
derivatives were calculated, smoothed using a 13-point Savitzky-Golay algorithm, and normal-
ized by vector normalization over the whole spectral range (Fig 2B). A quality test was applied
and data homogeneity (outlier identification) was visually checked by principal component
analysis (PCA).
Statistical analysis of spectra. The statistical analyses of spectra were aimed at identifying
patients at risk of death within 6 months. The wavenumber reduction process was performed
only in the first 90 patients to limit the risk of overlearning. Selection of significant wavenum-
ber within the initial set of 615 absorbance measures (3200–950 cm-1 with a 2800–1800 cm-1
gap, spectral step of 2 cm-1) was achieved using FADA algorithm [33]. Linear discriminant
analysis (LDA) classification error rate was used as a fitness function. The variable selection
process was run 200 times with a Monte Carlo cross validation of 10% [36]. The most fre-
quently selected wavenumber (around 30) during the 200 runs were retained. Once that data-
set was chosen, the LDA was run with a 90%/10% Monte Carlo cross-validation, repeated 100
times, and supervised attempts to further reduce and optimize this variable set. Once the
MIR-FEWS for the prognosis of cirrhosis with ascites
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optimized wavenumber set (a dozen) was defined, the LDA model was built using this set on
the entire population and performances were checked by 90%/10% Monte Carlo cross-valida-
tion (Fig 3).
Spearman’s tests were used to study the relationship between biological parameters and
spectral variables, and also between spectral variables.
All statistical analyses of spectra were performed in the R core environment [37] through
packages caret [38], FADA [39] and ROCR [40].
Results
Patients population
One hundred and nineteen patients with cirrhosis and ascites were prospectively included.
Three patients were transplanted before the follow-up visit and were excluded from analysis.
Clinical and biological characteristics of patients are summarized in Table 1.
Ninety-four (81%) patients were male with a mean age of 57.3±13.7 years. The mean
MELD score was 16.32 ± 6.26 and Child-Pugh score was 9.5 ± 1.8. One hundred and nine
patients had alcoholic liver disease (96%). Three patients had spontaneous bacterial peritonitis
and seven presented with encephalopathy. Fifty one patients had treatment with beta blockers,
26 with furosemide, 43 with spironolactone, and 48 with spontaneous bacterial peritonitis
prophylaxis.
The 6-month mortality rate was 20% (n = 23), and the main causes of death were liver fail-
ure (39%), sepsis (9%) and hemorrhage (13%). For 39% of patients, cause of death was either
unknown or not related to liver disease. Low sodium levels and prothrombin ratio (p<0.01),
increased INR (p<0.01), C-reactive protein levels (p<0.01), total bilirubin levels (p<0.01),
ALT and ALP levels (p<0.05), and elevated MELD (p<0.001) and Child Pugh scores
(p<0.001), were significantly associated with 6-month mortality (Table 1).
Six months mortality risk assessment
All spectra passed the quality test (adjusted from [41]) and two outliers were identified by PCA
analysis. These outliers were patients alive at 6 months. PCA analysis did not reveal any clear
Fig 3. Illustrative histogram of spectral variables selection by FADA algorithm and the process of
variable selection optimization for Mid-infrared predictive model construction. The red line shows the
minimum for variable selection.
https://doi.org/10.1371/journal.pone.0185997.g003
MIR-FEWS for the prognosis of cirrhosis with ascites
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discrimination (i.e. no clustering) between deceased and not deceased patients. This prompted
the use of a supervised method (LDA) with variable selection.
Representative spectra of one patient deceased and one alive at 6 months are displayed in
Fig 4. Second derivative spectra showed differences between the two patients groups, but only
Table 1. Clinical and biological characteristics of patients included.
Alive at 6 months
(n = 93)
Deceased at 6 months
(n = 23)
p
Age (years) 56.7 ± 14.4 59.9 ± 9.8 NS
Gender F/M 17/76 5/18 NS
Creatinine (mmol/l) 81.9 ± 51.2 127.2 ± 145.1 NS
Albumin (g/l) 30.0 ± 4.6 28.2 ± 5.1 NS
Bilirubin (μmol/l) 49.0 ± 54.1 144.6 ± 183.7 **
Prothrombin ratio 56.7 ± 13.6 46.6 ± 14.1 **
INR 1.58 ± 0.39 1.89 ± 0.45 **
Sodium (mmol/l) 135.8 ± 4.1 132.9 ± 3.9 **
AST (UI/l) 84.8 ±112.6 89.4 ± 52.6 NS
ALT (UI/l) 41.3 ± 56.5 44.3 ± 28.8 *
GGT (UI/l) 198.4 ± 184.9 255.8 ± 316.3 NS
CRP (mg/l) 19.7 ± 39.7 27.3 ± 24.5 **
ALP (UI/l) 151.2 ± 83.0 201.2 ± 121.1 *
MELD 14.9 ± 4.8 21.4 ± 8.2 ***
Child-Pugh 9.1 ±1.7 10.9 ± 1.6 ***
Values are mean ±SD.
*p<0.05.
**p<0.01.
***p<0,001 NS: non-significant.
https://doi.org/10.1371/journal.pone.0185997.t001
Fig 4. Representative spectra of one patient deceased (red) and one alive (blue) at 6 months. The seven
spectral variables selected to build the predictive model are represented by stars. A) Second derivative spectra
in the 3200–2800; 1800-950cm-1 domain. B) An expanded view in the 1530-1380cm-1 domain. C) An
expanded view in the 1090-950cm-1 domain.
https://doi.org/10.1371/journal.pone.0185997.g004
MIR-FEWS for the prognosis of cirrhosis with ascites
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a few of these differences were systematic. The MIR FEWS model eventually included 7 spec-
tral variables (Table 2).
The mean AUROC of MIR-FEWS model over 100 cross-validation runs was 0.90 (CI95:
0.88–0.91). A mean cut-off of 0.30 was chosen to maximize sensibility and specificity. This cut-
off yield a mean sensitivity of 0.79 (CI95:0.75–0.83) and specificity of 0.85 (CI95:0.84–0.87).
Detailed results of the cross-validation are presented Fig 5. One deceased and six surviving
patients were systematically misclassified over 100 runs of cross-validation. There was no clini-
cal or biological evidence to explain the misclassification of these patients.
To compare the accuracy between the MIR model, MELD and Child-Pugh scores, the MIR
model was determined for the entire population without Monte Carlo cross-validation. The
AUROCs for the MIR model was 0.94 (CI95: 0.87–0.99), MELD 0.77 (CI95: 0.66–0.89) and
Child-Pugh 0.76 (CI95: 0.66–0.88) (Fig 6). The AUROC of MIR-FEWS was significantly
higher than that of the MELD (p = 0.02) and the Child-Pugh score (p = 0.02). There was no sig-
nificant difference between the MELD and Child-Pugh AUROCs.
Table 2. Selected variable by FADA algorithm to discriminate patients alive or dead at 6 months.
Selected variables, wavenumbers (cm-1) Assignments
2925 νasCH2 acyl chains (stretching mode)
1496 Aromatic ring
1468 δCH2 (bending mode)
1316 Amide III, protein
1078 PO2- nucleic acid / C-C and C-O endo-ring in sugars
1030 ν(C = O); RNA and exo-ring in polysaccharides
972 δ;all trans lipid
ν and δ symbols feature the type of vibration: ν for stretching and δ for bending; as for asymmetric and s for
symmetric vibrational modes.
https://doi.org/10.1371/journal.pone.0185997.t002
Fig 5. Boxplots of AUROC, cut-off, sensibility and specificity values across the 100 runs of 90%/10%
Monte Carlo cross-validation for the MIR FEWS model. Boxplots of sensibility and specificity were
obtained with a 0.30 cut-off value.
https://doi.org/10.1371/journal.pone.0185997.g005
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Logistic regression multivariate analysis identified the MELD (p<0.05, OR:0.86; CI95:0.76–
0.97), the MIR model (p<0.001; OR:0.50;CI95:0.37–0.66), and beta blockers (p = 0.036;
OR:0.20;CI95:0.04–0.90) as significant variables to explain 6-month mortality.
Biochemical assignment of the spectral signature
Seven spectral variables (wavenumbers) were selected to build the MIR model. Chemical
bonds that can be related to these wavenumbers are summarized in Table 2. These results
show that 6 months mortality is associated with modifications of lipids, proteins, nucleic acids
and sugar fingerprints. Concerning the lipid cluster, the 2925 cm-1 and 1468 cm-1 bands fea-
ture the CH2 stretching and bending modes respectively. The 972 cm
-1 band can be assigned
to the all trans lipids modes. The 1316 cm-1 band arises from the protein amide III vibration
whereas the 1496 cm-1 band is associated to aromatic rings vibrations. The 1030 cm-1 band is
specific to sugars endo-ring vibrations whereas the 1078 cm-1 band can arise either from PO2
-
nucleic acids vibrations or from sugars exo-ring vibrations (only present in polysaccharides).
Some of these spectral markers have been already identified in sera of patients exhibiting vari-
ous diseases. For instance, the 1316 cm-1 marker was identified in sera of women exhibiting
breast cancer [42], its contribution to an early diagnosis being related to significant conforma-
tion alterations in circulating proteins. The 1496 cm-1 band, which features aromatic rings
vibrations, could be associated to nitrotyrosine–protein adducts as shown in mouse models of
acetaminophen–induced hepatitis [43]. This assumption is based on the vibrational effect of
the nitro group on the phenol ring vibration of Tyr amino acid residues. The 1078 cm-1 band
Fig 6. Comparison of receiver-operating characteristic (ROC) curves for the prediction of 6 months
mortality. MIR model (red) (AUROC:0.94, CI95: 0.87–0.99), MELD score (blue) (AUROC:0.77, CI95: 0.66–
0.89) and Child-Pugh score (AUROC: 0.76, CI95: 0.66–0.88) (black).
https://doi.org/10.1371/journal.pone.0185997.g006
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is more challenging to assign. Gautam et al. [44] assigned this marker to a DNA leak in serum
induced by cell necrosis.
It is noteworthy that spectral variables are correlated one with another (Fig 7A): 2925cm-1
is significantly correlated with 1468cm-1 (r = 0.53, p<0.001) and 972cm-1 (r = 0.21, p<0.05);
1496cm-1 is significantly correlated with 1316cm-1 (r = -0.43, p<0.001) and 1030cm-1 (r =
-0.22, p<0.05); 1468cm-1 is significantly correlated with 1316cm-1 (r = -0.26, p<0.01);
1078cm-1 is significantly correlated with 1030cm-1 (r = 0.19; p<0.05) and 972cm-1 (r = -0.19;
p<0.05). It must be pointed out that these markers have been identified from second derivative
spectra, therefore positive or negative correlation cannot be interpreted as similar or opposite
absorbency variations. The most important point is to emphasize that the network of markers
makes the recorded spectral signature and thus it is their relative variations as a whole which
bear disease information.
Linking spectral markers with clinical and biological markers
Five of the seven spectral markers were significantly correlated with biological parameters
evaluated in this study (Fig 7B): 2925cm-1 was significantly correlated with creatinine (r = 0.30,
p<0.001), bilirubin (r = 0.40, p<0.001), GGT (r = 0.37, p<0.001), ALP (r = 0.21, p<0.05), and
with the MELD score (r = 0.31, p<0.01); 1468cm-1 with creatinine (r = 0.27, p<0.01), sodium
(r = -0.19, p<0.05), bilirubin (r = 0.33, p<0.001), and with the MELD score (r = 0.24, p<0.05);
1316cm-1 with albumin (r = 0.21, p<0.05) bilirubin (r = -0.23, p<0.05), and with the Child-
Pugh score (r = -0.20, p<0.05); 1078cm-1 with GGT (r = -0.24, p<0.05); and 1030cm-1 with
sodium (r = -0.27, p<0.01).
Discussion
Our pilot study shows that MIR-FEWS for metabolic profiling of patients with cirrhosis and
ascites has a very good prognosis value. AUROC for six months mortality was 0.90(CI95:
Fig 7. Schematic illustrations of spectral and biomolecular networks. A) Shows the network of spectral biomarkers. Rather than individual values
at these 7 wavenumbers, the diagnostic prediction relies on the whole network as it is shown from the correlations between markers. Positive
correlations are featured with blue edges, negative with red ones. Edge’s thickness reflects the degree of correlation (r value). Every correlation is
significant (p<0.05 at least). B) Complete network of disease markers including spectral (blue), clinical and biological (red) markers and scores (green).
Correlations are coded as in (A).
https://doi.org/10.1371/journal.pone.0185997.g007
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0.88–0.91). A cut-off of 0.30 yielded a mean sensitivity of 0.79 (CI95:0.75–0.83) and specificity
of 0.85 (CI95:0.84–0.87). AUROC of MELD and Child-Pugh scores were significantly lower
than that of MIR model. In multivariate analyses MIR model, beta blockers treatment, and
MELD scores were significantly associated with death within 6-months.
Although numerous studies have been performed to assess prognosis scores in patients
with cirrhosis, few specifically assessed the prognosis of patients with ascites. In patients with
cirrhosis, several studies showed similar prognosis value of the MELD and Child-Pugh scores,
while others inconsistently favoured one over the other [45].
In a prospective work in patients with refractory ascites, Sersté et al. showed that the Child-
Pugh score had a higher AUROC to predict mortality than the MELDNa score. Furthermore,
severe hyponatremia was a better predictor of death than MELDNa [46]. In that study, Child-
Pugh score had a higher AUROC than in our study (0.89 versus 0.76 respectively), conversely,
MELD score had a lower AUROC than in our population (0.58 versus 0.77, respectively). This
may be explained by differences in study populations as our population was not restricted to
refractory ascites. Moreover our results were based on a 6 months restricted follow-up.
Most studies have been carried out with a 3-month follow-up and show AUROC for MELD
scores and Child-Pugh of about 0.85 [47–49]. More dedicated studies performed in patients
with uncompensated cirrhosis presented lower AUROC values of between 0.61 and 0.79 for
the Child-Pugh and 0.76 and 0.80 for the MELD [50,51] which are consistent with our results.
In order to prioritize patients for liver transplantation, MELD exception points had to be set
up to offset its lack of efficiency [52]. This emphasizes the unmet need for prognosis classifica-
tion in this setting.
Recent technological developments have highlighted the relevance of metabolic profiling in
patients liver disease to assess their outcome [53–55]. Discrete description of metabolic alter-
ations in serum of patients recently showed excellent performance in predicting survival of
patients with uncompensated cirrhosis [56]. Although direct comparisons with available prog-
nosis scores were not performed in this study, it supports the potential benefit of metabolic
profiling. Limitations of the method used in that study include its complexity, expensive equip-
ment and analyses required to implement these metabolomics tests. Our study uses a simple
benchtop method which, although not giving a definite picture of the various metabolic alter-
ations, provides a global fingerprint that shows satisfactory prognosis assessment. The pattern
approach used in our study emphasizes the relevance of relative variations in identified spec-
tral markers, which is facilitated by the fact that MIR spectra feature a wide range of relevant
metabolites.
In conclusion, compared with the MELD and Child-Pugh scores, the MIR-FEWS method
appears to be more efficient at identifying patients at risk for short-term mortality. This could
be related to the ability of MIR-FEWS to obtain global information on the metabolic status of
patients, in contrast to conventional scores which are based upon a limited number of parame-
ters. The relevance of MIR-FEWS should be confirmed in an independent and large cohort of
patients with cirrhosis and ascites. In addition, our study suggests the relevance of using the
MIR-FEWS method in patients with cirrhosis with or without ascites.
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15. Anne M-L, Le Lan C, Monbet V, Boussard-Plédel C, Ropert M, Sire O, et al. Fiber evanescent wave
spectroscopy using the mid-infrared provides useful fingerprints for metabolic profiling in humans. J
Biomed Opt. 2009; 14: 054033. https://doi.org/10.1117/1.3253319 PMID: 19895135
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